Congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency is an autosomal recessive disease, which leads to cortisol and aldosterone deficiency and hyperandrogenism. Typical medical treatment includes oral glucocorticoid and mineralocorticoid administration to suppress adrenal androgens and to compensate for adrenal steroid deficiencies. However, some patients stopped taking medicine without the doctor's consent. Among these patients, four cases of CAH patients showing the presence of hyponatremia as an initial electrolyte disorder were found with adrenal adenoma. Hypersecretion of adrenocorticotrophic hormone and chronic poor compliance to therapy appears to be associated with the development of the adrenal tumor. Two cases were managed with adrenalectomy because of increasing adrenal tumor size and virilization. Whereas the other two cases did not increase in size and were observed without adrenalectomy. Therefore, it is important that patients with CAH maintain steroid medication to avoid the appearance of adrenal tumor.
Introduction
Congenital adrenal hyperplasia (CAH) is caused by defects in various enzymes necessary for cortisol synthesis. 90-95% of CAH cases are caused by 21-hydroxylase deficiency . In patients with 21-OHD, poor synthesis of cortisol results in chronic stimulation of the adrenal cortex. This results in overproduction of cortisol precursors. Some of these precursors are shunted into the androgen synthetic pathway, causing signs and symptoms of androgen excess, including ambiguous genitalia in females and rapid somatic growth with accelerated skeletal maturation in both sexes 1) .
Since the discovery of cortisone in the 1950s, CAH has been managed effectively, and the clinical course of the disease has markedly improved 2) . Typical medical treatment consists of oral glucocorticoid and mineralocorticoid administration in order to compensate for adrenal steroid deficiencies and to suppress adrenal androgens.
Herein, we report four cases of patients who were diagnosed as having CAH. They have been managed with hydrocortisone and fludrocortisone. But the patients stopped taking medicine without the doctor's consent. Thereafter, adrenal masses were found by abdominal computed tomography (CT) scan in all four cases. Recent reports reveal a high apprearance of small tumors in patients with untreated CAH and most adrenal masses in children with CAH are benign [3] [4] [5] . Two of our four cases were managed with adrenalectomy because of increasing adrenal mass size and virilization. The size of the other two cases did not increase. So they were treated conservatively without adrenalectomy.
Case Report
Clinical features of 4 patients are shown in 
Case 2
A female neonate presented with ambiguous genitalia at birth suggesting salt-losing CAH. Hydrocortisone and fludrocortisone were initiated. When she was at the age of 3 years, vaginoplasty and clitoroplasty were performed. At the age of 11, she showed breast budding and pubic hair. Masculine voice and virilization were also present. Abdominal CT performed at the age of 11 years showed a 3.5 4.0 cm mass in × her right adrenal gland (Fig. 2) . Adrenal mass was assumed to be an adrenal adenoma. Right adrenalectomy was performed at the age of 12 years. Abdominal CT showed the presence of multiple bilateral adrenal masses. B) Abdominal CT performed at the age of 20 years. Abdominal CT showed that adrenal masses on both sides were increased in size.
Case 3
A female neonate showed ambiguous genitalia at birth. She was diagnosed as having 21-OHD CAH.
Hydrocortisone and fludrocortisone administration was carried out during follow-up and vaginoplasty and clitoroplasty were performed at the age of 4 years.
When she was 11 years old and 12 years old, abdominal CTs were performed due to her virilization including hirsuitism and masculine voice. They revealed adrenal hyperplasia without change in size. There was no remarkable finding of her adrenal mass
Case 4
A male neonate was admitted to medical attention at 1 month of age with poor oral intake and diarrhea. He was diagnosed with renal tubular acidosis type IV. He was discharged after his oral intake and diarrhea im- . In 95% of cases, 21-OHD is responsible for the disease 7) . . Proximity to the HLA histocompatibility complex is a cause of high rate of recombination.
The pathophysiology of CAH due to 21-OHD is closely linked to the degree of enzyme deficiency 6) .
The biosynthesis of cortisol is regulated by negative feedback on hypothalamic corticotropin-releasing hor- . Boys with the salt-losing form typically present at 7-14 days of life with vomiting, weight loss, lethargy, dehydration, hyponatraemia, hyperkalaemia, and can present shock.
Patients with non-classic CAH do not have cortisol deficiency, but instead have manifestations of hyperandrogenism, generally later in childhood or in early adulthood 13, 14) . There is no prenatal virilization. Post- [15] [16] [17] . To achieve these goals, the glucocorticoid doses have to exceed the physiological cortisol secretion rate, using doses of 12-18 mg/m 2 hydrocortisone daily divided into two or three doses 10) . Hydrocortisone is the glucocorticoid of choice during childhood 18) .
Mineralocorticoid replacement is achieved with fludrocortisone. Fludrocortisone was administered in cases of salt-losing manifestation and elevated plasma renin activity, to decrease glucocorticoid doses, or according to the genotype 19) . The use of fludrocortisone in patients with non-salt-losing classic CAH allows management with lower doses of glucocorticoid and improves linear growth [18] [19] [20] . Infants with the saltlosing form of 21-OHD require mineralocorticoid (fludrocortisone, usually 0.1-0.2 mg) and sodium chloride supplements (1-2 g daily; 1 g NaCl contains 17 mEq of sodium) in addition to glucocorticoid treatment.
Many patients with the non-classic CAH do not need treatment. Treatment is indicated only for those with symptoms and aims to reduce hyperandrogenism [18] [19] [20] .
CAH constitutes a continuum of disorders that affect patients throughout their lives (Table 2) . A variety of clinics involving close interaction between paediatric, reproductive, adult endocrinologists, and clinical psychologists experienced in psychosexual counselling will be necessary for patients with CAH [21] [22] [23] [24] .
The development of adrenal adenoma or carcinoma in patients with CAH is rare; the etiology is not clear.
However, the incidence of adrenal masses appears to be higher in CAH patients and in heterozygotes than in the general population 3) . Recent reports have revealed a high prevalence of small adrenal tumors in patients with untreated 21-OHD CAH 3, 4) . Histological types of adrenal tumor include adenoma, myelolipoma, and hemangioma 25) . Rarely, virilizing adrenal carcinoma has been found in patients with CAH, but most adrenal masses in children with CAH are benign 5) . The pathogenesis of adrenal tumor in patients with 21-OHD CAH is thought to be related to a consequence of ACTH hypersecretion, which results from the lack of glucocorticoid synthesis 26) . Avoidance of high steroid dose is likely to result in insufficient suppression of corticotropin stimulation 27) . 
